European Journal of Pediatrics最新文献

{"title":"Why think twice before prescribing proton pump inhibitors.","authors":"An-Sofie Lemmens, Koen Huysentruyt, Yvan Vandenplas","doi":"10.1007/s00431-025-06058-z","DOIUrl":"10.1007/s00431-025-06058-z","url":null,"abstract":"<p><p>Proton pump inhibitors (PPIs) represent a class of drugs most prominently known for their use in acid-related disorders. Omeprazole, a drug belonging to this class, is among the top 10 most prescribed drugs in the USA. PPIs have a direct effect on the gastric pH and therefore on the gastric mucosa. This review aims to present the most common adverse effects PPIs have on the gastric mucosa in particular.</p><p><strong>Conclusion: </strong>PPIs affect the composition of gut and gastric microbiota and will eventually modulate the immune response.</p><p><strong>What is known: </strong>• Proton-pump inhibitors are amonth the most frequent prescirbed drugs becasue of their well demonstrated efficacy in acid-related disorders. • Because of their mode of action and their metabolism, a large spectrum of adversee effects have been reported.</p><p><strong>What is new: </strong>• Although the well-known success of PPIs in the wide spectrum of all acid-related conditions should not refrain health care professionals to use them when indicated, insufficient attention is given to the multiple adverse effects reported for this class of drugs. • Well designed prospective trials collecting adverse effects are required, since most studies reporting adverse effects are retrospective, are biassed and have methodological issues.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"184 3","pages":"227"},"PeriodicalIF":3.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective study.","authors":"Alexis Marouk, Bernadette Verrat, Isabelle Pontais, Dumitru Cojocaru, Hélène Chappuy, Irina Craiu, Pauline Quagliaro, Vincent Gajdos, Valérie Soussan-Banini, Yves Gallien, Anne-Laure Feral-Pierssens","doi":"10.1007/s00431-025-06050-7","DOIUrl":"10.1007/s00431-025-06050-7","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) is a leading cause of infant morbidity. France has implemented a national campaign using nirsevimab to prevent RSV-related infections in infants. This study assessed its effectiveness in preventing hospitalization due to bronchiolitis in emergency department (ED). This retrospective study was conducted among six pediatric EDs in the Greater Paris area, France, and included infants aged < 3 months with a clinical diagnosis of bronchiolitis during the 2023-2024 RSV epidemic season. The primary outcome was hospitalization after the ED visits. The association with nirsevimab immunization was assessed using a multiple logistic model adjusted for potential confounding factors, with missing data handled using random forest imputation. Secondary analyses examined the risk of admission to the pediatric intensive care unit (PICU), RSV positivity, and subgroup analyses of prematurity, neonates, and deprivation using the FDep index (area-based measure of social deprivation in France). Between October 2 and December 31, 2023, 739 infants were included in the study. A total of 531 (72%) patients had a documented nirsevimab immunization status, and 402 (54%) were hospitalized following a bronchiolitis diagnosis. Nirsevimab showed 53.5% adjusted effectiveness in reducing hospitalizations (95% CI 34.1-67.3). Sensitivity analyses of complete-case data and propensity score matching yielded similar results. Nirsevimab also resulted in 51.1% reduction in PICU admissions (95% CI 10.7-74.3) and 79.6% reduction in RSV positivity (95% CI 68.0-87.1). The protective effect of immunization was consistent for preterm infants, neonates, and deprived groups, though the results were not statistically significant in these smaller subgroups.</p><p><strong>Conclusions: </strong>Immunization with nirsevimab reduced hospitalization following an ED visit for bronchiolitis among infants aged < 3 months.</p><p><strong>What is known: </strong>• Nirsevimab reduces the risk of bronchiolitis-related hospitalizations in clinical trials. • Real-world data from the immunization campaign in France remain limited.</p><p><strong>What is new: </strong>• Nirsevimab showed 53.5% (95% CI 34.1-67.3) adjusted effectiveness in reducing hospitalizations for all-cause bronchiolitis in infants aged < 3 months in emergency departments. • Analyses included social deprivation and highlighted potential disparities in immunization access.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"184 3","pages":"229"},"PeriodicalIF":3.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Higher bone mineral density at six years of age in very preterm-born infants fed human milk compared to formula feeding. A secondary analysis of an RCT.","authors":"Line H Toftlund, Signe Sparre Beck-Nielsen, Lone Agertoft, Susanne Halken, Gitte Zachariassen","doi":"10.1007/s00431-025-06045-4","DOIUrl":"10.1007/s00431-025-06045-4","url":null,"abstract":"","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"184 3","pages":"224"},"PeriodicalIF":3.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age differences in prevalence and symptoms of post-COVID-19 condition among children: a prospective cohort study.","authors":"Yixin Wu, Xiangrong Sun, Jingyun Yang, Hailin Fan, Ouxuan Jin, Liwei Tang, Meixian Zhang, Lizhen Wang","doi":"10.1007/s00431-025-06064-1","DOIUrl":"10.1007/s00431-025-06064-1","url":null,"abstract":"<p><p>Some individuals experience unexplained, persistent, or newly developed symptoms after coronavirus disease 2019 (COVID-19), known as post-COVID-19 condition (PCC). We explored the age-related prevalence, symptoms, and associated factors for PCC in children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This prospective cohort study enrolled children with SARS-CoV-2 infection between December 7, 2022, and January 31, 2023. The participants were assessed via telephone 6 months post-SARS-CoV-2 diagnosis. PCC in children was diagnosed according to the World Health Organization definition. In total, 1084 patients were eligible for matching and follow-up. Eventually, 785 patients (follow-up rate, 72.4%) completed the follow-up. The incidence of PCC among pediatric patients with COVID-19 was 8%. The most common symptom reported by children diagnosed with PCC in all age groups was fatigue. For patients aged 0-2 years, the presence of gastrointestinal symptoms (OR,6.323; 95% CI, 1.549-25.818) and neurological symptoms (OR, 3.816; 95% CI, 1.075-13.545) at the onset of COVID-19 were associated factors for PCC. For patients aged 3-6 years, no associated factors associated with PCC were identified. For patients aged 7-12 years, preexisting comorbidities (OR, 6.869; 95% CI, 2.209-21.360) were associated factors for PCC. For patients aged 13-17 years, female sex (OR, 3.635; 95% CI, 1.164-11.355) and preexisting comorbidities (OR, 6.295; 95% CI, 2.052-19.316) were associated factors for PCC.</p><p><strong>Conclusion: </strong>The incidence of PCC among pediatric patients with COVID-19 was 8%, with fatigue being the most commonly reported symptom across all age groups. The associated factors for PCC varied according to age groups.</p><p><strong>What is known: </strong>• Post-COVID-19 condition (PCC) can significantly affect the psychological and physiological health of children. •The characteristics of persistent symptoms and the incidence of PCC varied among children of different age groups.</p><p><strong>What is new: </strong>• Fatigue is the most common symptom of PCC in children of all age groups. • The associated factors for PCC varied according to age group.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"184 3","pages":"228"},"PeriodicalIF":3.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and effectiveness of a biosimilar somatropin (Cinnatropin®) in children and adolescents receiving growth hormone therapy over 1 year: a registry-based phase IV study.","authors":"Ali Rabbani, Maryam Razzaghy-Azar, Zohreh Karamizadeh, Mahin Hashemipour, Rahim Vakili, Aria Setoodeh, Mohammadreza Alaei, Robabeh Ghergherehchi, Shadab Salehpour, Majid Aminzadeh, Ali Talea, Hossein Zaeri, Mahmoud Ghasemi, Forough Saki, Araz Sabzvari, Hamidreza Kafi","doi":"10.1007/s00431-025-06056-1","DOIUrl":"10.1007/s00431-025-06056-1","url":null,"abstract":"<p><p>Growth hormone therapy has been shown to be effective in treating a variety of growth-related disorders. This post-marketing study assessed the effectiveness and safety of Cinnatropin®, a biosimilar growth hormone product. The data from the Orchid-Life Registry, which collects long-term effectiveness and safety data from patients receiving Cinnatropin®, was analyzed. A total of 20,465 patients were enrolled in this study, including 405 subjects in the longitudinal analysis. The most common diagnosis was growth hormone deficiency. The mean (SD) height standard deviation score (HSDS) increased from - 1.71 (1.31) to - 1.32 (1.26) in the cross-sectional population and from - 1.84 (1.18) to - 1.49 (1.13) in the longitudinal population over a period of 12 months. The baseline age exhibited an inverse correlation with changes in HSDS, suggesting that older individuals had smaller increments. Over 80% of prepubertal patients reached targeted height velocity after 1 year of treatment. The majority of adverse events were categorized as non-serious, designated as grade one in severity (mild). The most frequently observed adverse events were injection site reaction and headache. Conclusion: The study indicates that Cinnatropin® treatment results in height improvement over 1 year with an acceptable safety profile.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"184 3","pages":"226"},"PeriodicalIF":3.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing sleep habits in school-aged children with phenylketonuria: a comparative study.","authors":"Ayşe Mete Yeşil, Halil Tuna Akar, Yılmaz Yıldız, Serap Sivri, Elif N Özmert","doi":"10.1007/s00431-025-06048-1","DOIUrl":"10.1007/s00431-025-06048-1","url":null,"abstract":"<p><p>Phenylketonuria (PKU) is an autosomal recessive metabolic disorder characterized as deficiencies in phenylalanine hydroxylase, leading to neurotoxic effects and neurodevelopmental challenges. Sleep, crucial for cognitive and behavioral development, remains underexplored in PKU populations. This study evaluates sleep characteristics and influencing factors in school-aged children with PKU compared to those with hyperphenylalaninemia (HPA) and healthy controls. A total of 101 children aged 5-10 years participated: 37 with PKU, 31 with HPA, and 33 healthy controls. Sleep quality and disturbances were assessed using the Children's Sleep Habits Questionnaire (CSHQ) and parent-reported data. Additional factors, including phenylalanine levels and sleep hygiene practices, were analyzed. Despite no significant differences in total CSHQ scores across groups, children with PKU exhibited unique patterns, such as being less likely to awaken by himself or herself. Phenylalanine levels showed no significant correlations with overall sleep characteristics, except for an association with reduced sleep anxiety. Distinct sleep hygiene influences emerged in the HPA and control groups, while no such relationships were observed in PKU. This study underscores the complexity of sleep disturbances in PKU, highlighting the need for future research integrating biological, behavioral, and environmental factors. Identifying determinants of sleep problems will aid in developing tailored interventions to enhance the quality of life for patients with PKU. What is known: • Children with PKU, in addition to the risks associated with chronic illness, may be more susceptible to sleep disturbances due to metabolic and neurochemical imbalances. • Prior studies on PKU and sleep have mainly focused on adult populations, with limited data available for school-aged children. What is new: • The sleep characteristics of PKU, HPA, and healthy controls were generally similar, except for awakening by themselves. • Distinct sleep hygiene influences were identified in the HPA and control groups, while no such associations were observed in the PKU group, highlighting the need for a broader perspective to explore alternative biological, behavioral, and environmental factors affecting sleep regulation in PKU.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"184 3","pages":"225"},"PeriodicalIF":3.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the safety of doxapram in premature neonates born before 28 weeks of gestation.","authors":"Lauren Saade, Elodie Zana-Taïeb, Pierre-Henri Jarreau, Valérie Biran, Mouna Loukil, Ludovic Tréluyer, Héloïse Torchin","doi":"10.1007/s00431-025-06054-3","DOIUrl":"10.1007/s00431-025-06054-3","url":null,"abstract":"<p><p>To assess the short-term safety of doxapram for treating apnea of prematurity. This is a retrospective and bicenter study. Eligible children were born before 28 weeks of gestation from January 1, 2020 to December 31, 2021. The association between doxapram treatment and gastrointestinal events was assessed with logistic regression models with adjustment for the main confounding factors: center, sex, intra-uterine growth restriction and gestational age. The main outcome measures are gastrointestinal events (necrotizing enterocolitis or feeding intolerance), the adverse effects of doxapram most frequently reported in the literature. The population consisted of 268 children; 113 (42.2%) received doxapram. As compared with children who did not receive doxapram, those who did had lower gestational age at birth (25.4 vs 26.3 weeks), lower birth weight and more evidence of greater clinical respiratory severity. Doxapram treatment was not associated with increased risk of gastrointestinal events (30.1% and 29.7% in the treated and untreated groups; odds ratio 1.3, 95% CI 0.7-2.4, p = 0.43). More children in the treated than untreated group had high blood pressure (25.7% vs 6.5%).</p><p><strong>Conclusion: </strong>In children born before 28 weeks of gestation, doxapram treatment for apnea of prematurity was not associated with the occurrence of gastrointestinal events.</p><p><strong>What is known: </strong>• Doxapram is a well-known second-line treatment for apnea of prematurity. It is a central nervous stimulant that can be used in refractory apnea of prematurity despite continuous positive airway pressure and optimal caffeine therapy. However, its use varies among countries and centers, probably because of suspected adverse effects. Studies suggest that this drug may have potential side effects such as digestive events (necrotizing enterocolitis).</p><p><strong>What is new: </strong>• We present reassuring data on the digestive safety of doxapram. Use of this drug was not associated with increased rates of digestive events in preterm infants born before 28 weeks of gestation.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"184 3","pages":"222"},"PeriodicalIF":3.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary artery dilation in children with MIS-C: prevalence, risk factor, and progression.","authors":"Phung Nguyen The Nguyen, Tran Thanh Thuc, Nguyen Thanh Hung, Nguyen Tri Hao, Nguyen Minh Tri Viet, Nguyen Thi Ngoc Phuong, Vu Thi Thuy Trang, Le Minh Hieu, Phan Dai Bang, Nguyen Thi Mai Thao, Huynh Nguyen Anh Thu","doi":"10.1007/s00431-025-06051-6","DOIUrl":"10.1007/s00431-025-06051-6","url":null,"abstract":"<p><p>Cardiac injury is the critical issue in children with MIS-C, particularly coronary artery dilation. This study aimed to describe the prevalence, risk factors associated with coronary artery abnormalities, and their progression after 3 months of follow-up in MIS-C children in Vietnam. A prospective multicenter case series study was conducted on MIS-C patients diagnosed per WHO criteria from September 2021 to February 2023 at the two largest pediatric hospitals in southern Vietnam. Data on demographics, clinical features, laboratory findings, and treatments during the acute phase of MIS-C were collected. Patients were followed for 3 months post-discharge and categorized into normal and abnormal coronary artery groups for comparative analysis. Among 195 patients (mean age 6.3 years; male to female ratio 1.5:1), 33.3% exhibited coronary artery abnormalities at admission. Treatment included a combination of intravenous immunoglobulin (IVIG) and corticosteroids (53.3%), corticosteroids alone (42.6%), and IVIG alone (4.1%). After 3 months, only 3.6% of patients had persistent coronary artery abnormalities. Independent risk factors for coronary artery dilation included male sex (OR 4.59; 95% CI 1.62-12.94; p = 0.004), Kawasaki-like phenotype (OR 6.42; 95% CI 2.25-18.33; p = 0.001), and mesenteric lymphadenitis (OR 8.79; 95% CI 1.74-44.31; p = 0.008).</p><p><strong>Conclusion: </strong>Coronary artery dilation in MIS-C patients shows a favorable recovery trajectory after a 3-month follow-up. Male sex, Kawasaki-like MIS-C, and mesenteric lymphadenitis are independent risk factors for coronary artery dilation in MIS-C patients.</p><p><strong>What is known: </strong>• Multisystem inflammatory syndrome in children (MIS-C) is a severe inflammatory syndrome following SARS-CoV-2 infection, often leading to cardiac complications, particularly coronary artery dilation.</p><p><strong>What is new: </strong>• Coronary artery dilation in MIS-C patients mostly resolves within three months of follow-up. Factors associated with coronary artery dilation in MIS-C patients include: male sex, Kawasaki-like phenotype and mesenteric lymphadenitis.</p>","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"184 3","pages":"221"},"PeriodicalIF":3.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Relationship between overweight and obesity and cardiac dimensions and function in a paediatric population.","authors":"Juan Fernández Cabeza, Cristhian H Aristizábal-Duque, Isabel María Blancas Sánchez, Martín Ruíz Ortiz, Ana Rodríguez Almodóvar, Mónica Delgado Ortega, Fátima Esteban Martínez, Manuel Romero Saldaña, Francisco Javier Fonseca Del Pozo, Manuel Pan Álvarez-Ossorio, María Dolores Mesa Rubio","doi":"10.1007/s00431-025-06061-4","DOIUrl":"10.1007/s00431-025-06061-4","url":null,"abstract":"","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"184 3","pages":"220"},"PeriodicalIF":3.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Facilitators and barriers to the transition from outpatient clinic visits to home-based check-ups for children being treated with growth hormone: a mixed-methods study.","authors":"Anouk J W Remmits, Ghislaine A P G van Mastrigt, Silvia M A A Evers, Petra A van Setten","doi":"10.1007/s00431-025-06036-5","DOIUrl":"10.1007/s00431-025-06036-5","url":null,"abstract":"","PeriodicalId":11997,"journal":{"name":"European Journal of Pediatrics","volume":"184 3","pages":"216"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}